Research influence on antimalarial drug policy change in Tanzania: Case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug

Malaria Journal

Volumn 4, Issue , 2005, Pages

  Mubyazi, Godfrey M ^a   Gonzalez Block, Miguel A ^b  

^a NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; NEW DRUG; QUININE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INTERVIEW; LIBRARIAN; MALARIA; MALARIA CONTROL; MEDICAL ETHICS; MEDICAL PERSONNEL; MEDICAL RESEARCH; PRACTICE GUIDELINE; TANZANIA; TREATMENT FAILURE; UNIVERSITY;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; HEALTH POLICY; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; RESEARCH; SULFADOXINE; TANZANIA; WORLD HEALTH ORGANIZATION;

EID: 27744499258     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-4-51     Document Type: Article

References (38)

1. UNICEF: Malaria: a major cause of child death and poverty in Africa. United Nations Children's Fund (UNICEF), New York; 2004.
2. Breman JG, Alilio MS, Mills A: Conquering the intolerable burden of malaria: what is needed: a summary. Am J Trop Med Hyg 2004, 71(suppl 2):1-15.
3. WHO: Facts on ACTs (Artemisinin-based Combination Therapies): an update on recent progress in policy and access to treatment. 2004 [http://www.rbm.who. int/pdf]. World Health Organization
4. EANMAT: Monitoring antimalarial drug resistance within national malaria control programmes: the EANMAT experience. Trop Med Int Health 2001, 6:1-8.
5. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W: Chlorproguanil-dapsone for treatment of drug resistant falciparum malaria in Tanzania. Lancet 2001, 358:1218-1223.
6. Abdulla S, Goodman C, Coleman P, Mubyazi G, Kikumbih N, Okorosobo T: The Costs, Effects and Cost-Effectiveness of Changing the First-Line Drug for the Treatment of Malaria in Tanzania. Health Economics and Financing Programme (HEFP), LSHTM. Working Paper No. 01/00 produced in February 2000 [http://www.malariaconsortium.org].
7. Mubyazi GM: The role of Research in changing the first-line antimalarial drug policy in Tanzania. Working Paper. 2003 [http://http:/www.alliancehpsr.int] . Alliance For Health Policy and Systems Research (AHPSR), Geneva
8. Schellenberg JA, Mponda H, Abdulla S, Nathan R: Improving child survival in rural Tanzania: Insecticide treated nets for malaria control in the Kilombero Valley. The KINET Project Overview. A report submitted by the Swiss Tropical Institute in collaboration with the Ifakara Health Research and Development Centre to the Ministry of Health of Tanzania and the Swiss Development Co-operation 2000.
9. Kitua AY: Antimalarial drug policy in Tanzania: making a systematic change. Lancent 1999, 354:2.
10. Ministry of Health - Tanzania: Summary report of the Task Force on Antimalarial Drug Policy, Tanzania. Ministry of Health, Dar Es Salaam. 1999, July 23
11. Ministry of Health - Tanzania & WHO-Country Office, Tanzania: Plan of action for accelerated implementation of malaria control in Tanzania. Unpublished Report, January 1999 & Revised in February 1999.
12. Ministry of Health - Tanzania: National guidelines for malaria diagnosis and treatment: Malaria Control Series. Ministry of Health, Dar Es Salaam; 2000.
13. Kitua AY: Antimalarial drug policy in Tanzania: making a systematic change. Lancent 1999, 354:32.
14. Mubyazi GM: The role of Research in changing the first-line antimalarial drug policy in Tanzania. Working Paper. 2003 [http://http:/www.alliancehpsr.int] . Alliance For Health Policy and Systems Research (AHPSR), Geneva
15. Mubyazi GM: Public perceptions of malaria and their utilization of modern and traditional medicines in Korogwe district, Tanzania. Tanzania Health Research Bulletin 2005, 7:88-93.
16. Hanney SR, Gonzalez-Block M, Kogan M: The utilisation of health research in policy-making: concepts, examples and methods of assessment. In A report of the Research Policy and Cooperation Department World Health Organization, Geneva; 2002.
17. TANHERF-Tanzania: Tanzania National Health Research Forum, Priority Setting Workshop 15-21 February 1999, Arusha International Conference Centre. In Final Report ENHR Secretariat, NIMR Dar Es Salaam; 1999.
18. TEHIP: Completing the circle: bringing research into development: antimalarial combination therapy. A Newsletter of the IDRC/MoH/Tanzania Essential Health Interventions Project 2000:15.
19. TEHIP: On evidence-based planning. TEHIP Newsletter 1999, 1(1): [http://www.idrc.ca.tehip].
20. Yin RK: Case study research: Designs and Methods. 2nd edition. Sage Publications: Thousand Oaks, CA. London; 2004.
21. Clyde D: Observation on monthly pyrimethamine (Daraprim) prophylaxis in an East African village. East African Medical Journal 1954, 3:41-46.
22. Clyde D, Shute G: Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg 1957, 51:505-513.
23. Antimalarial Drug Task Force-Tanzania: Drug policy: implementation of new treatment in Tanzania: the rationale for change to guide policy implementation. Tanzania Health Research Bulletin 2000, 2:10-13.
24. Mutabingwa TK, Maxwell CA, Sia IG, Msuya FH, Mkongewa S, Vannithone S, Curtis J, Curtis F: A trial of proguanil-dapsone in comparison with sulfadoxine pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans R Soc Trop Med Hyg 2001, 95:433-438.
25. Goodman C, Abdulla S, Coleman P, Mubyazi G: Would the replacement of chloroquine with SP be cost-effective in Tanzania? Malaria Consortium 2000 [http://www.malariaconsor tium.org].
26. Goodman C, Abdulla S, Coleman P, Mubyazi G, Kikumbih N, Okorosobo T, Mills A: Choosing the first line drug for malaria treatment-how can cost-effectiveness analysis inform policy? In Economics of Infection, Chapter 2 Edited by: Roberts J. Open University Press, London, UK in press.
27. TEHIP: Ministry of Health clarifies changes on malaria treatment. TEHIP Newsletter 2003:13 [http://www.idrc.ca.tehip].
28. TANHERF-Tanzania: Tanzania National Health Research Forum, Priority Setting Workshop 15-21 February 1999, Arusha International Conference Centre. In Final Report ENHR Secretariat, NIMR Dar Es Salaam; 1999.
29. Rønn A, Msangeni H, Mhina J: High level of resistance of Plasmodium falciparum to salfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996, 54:197-181.
30. TEHIP: Completing the circle: bringing research into development: Antimalarial combination therapy. TEHIP Newsletter :15.
31. Ralston S, Voltair's Bastards: The dictatorship of reason in the West. New York, the Free Press; 1992:584-585.
32. Medecins sans Frontieres: Act Now - Malaria Report. Médecins sans Frontières (MSF). (April 2003: http:://www.msf.org) and http://www.doctorswithoutborders.org/updated/publications/reports/ 2003/act now report.pdf updated with detailed country cases and protocols for ACT treatment at http://www.msf.fr/documents/paludisme/palu2004.pdf
33. MoH-Tanzania: Diagnosis and treatment of malaria: Orientation Guide for District Trainers. Malaria Control Series 10. National Malaria Control Programme 2005.
34. Wyss K: Malaria Update. A commissioned discussion paper established in the context of the mandate t.751-14 of the Swiss Development Cooperation 2002.
35. Bloland PB: Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 2000, 78:1378-1388.
36. Hanson K, Goodman C, Lines J, Meek S, Bradley D, Mills A: The economics of malaria control interventions. In Global Forum for Health Research WHO, Geneva; 2004.
37. Greenwood B: Malaria first, roll-back expectations. Bull World Health Organ 2000, 78:1451-1453.
38. Eisenberg JM: Globalize the evidence, localize the decision. Evidence-based evidence and international diversity. Health affairs 2002, 2:167.